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ABSTRACT 
Introduction: Dyslipidemia, which includes hypercholesterolemia and reduced 
level of HDL-C are the major reason for increased risk of atherogenesis. The 
sedentary life style &genetic disorders with diets rich in saturated fat & cholesterol 
contributes this non communicable disease. The drugs most commonly used for 
dyslipidemia are statins and fibrates.  Though the therapy may be started with 
either statin or fibrates, ultimately most of these patients require both the drugs or 
some other combination therapy. 
Methods: Eligible patients with dyslipidemia were randomly allotted into 2 equal 
groups- daily regime group (group 1) and alternate regime group (group 2). 
Patients in group 1 received atorvastatin 10 mg and fenofibrate 160 mg daily and 
group 2 received on alternate days, respectively for 6 weeks & follow up by 12th 
week. Mean percentage change from baseline in total cholesterol (TC), 
triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), VLDL-C, HDL-
C and TC-HDL ratio, incidence of adverse effects, and cost-effectiveness were 
compared in both the groups. 
Results: Among 93 patients screened, 60 were randomized into 2 groups as group1 
& 2 with 30 patients in each. The TC, LDL-C,TGs,VLDL-C decreased by 46.03%, 
47.23%, 58.67%, and 45.39% in alternate regime group and by 46.67%, 48.01%, 
59.88%, and 46.31% in daily regime group. The HDL-C levels increased by 
29.32% in alternate day therapy group compared to 32.11% in daily therapy group. 
No statistically significant difference was seen between both the groups in mean 
percentage change in lipid parameters from baseline to end of 12 weeks. TC-HDL 
ratio was 3.50 in group1 and 3.54 in group 2.Incidence of adverse events were 
reasonably less in alternate day therapy group. 
Conclusion: Alternate regime of atorvastatin 10 mg on one day & fenofibrate 160 
mg on other day is equally efficacious to daily regime of both atorvastatin10 mg 
and fenofibrate 160 mg with better cost effectiveness & better patient compliance 
in patients with secondary dyslipidemia. 
KEYWORDS: 
Alternate regime, atorvastatin, fenofibrate, cost-effectiveness, dyslipidemia 
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INTRODUCTION 
               Dyslipidemia is one of the most important risk factor predisposing for the 
ischemic cardiovascular diseases, cerebro vascular diseases and peripheral vascular 
diseases
1
. This is an important cause for morbidity and mortality among middle 
aged & older adults worldwide. 
              Dyslipidemia, which includes hypercholesterolemia and decreased level 
of HDL-C are the major reason for increased risk of atherogenesis. The sedentary 
life style &genetic disorders with diets rich in saturated fat & cholesterol 
contributes this non communicable disease 
1
. Nowadays, increased mortality is 
attributable to non communicable diseases & more than half of these are due to 
cardiovascular diseases. The main reason being hyperlipidemia; more than one 
third occurs in middle aged adults. 
              The current NCEP Adult Treatment Panel (ATP) III guidelines (updated 
in 2004) for managing dyslipidemia is primordial prevention that targets cessation 
of smoking, weight management,exercise,healthy eating habits, low cholesterol 
and glucose levels & maintaining normal BP 
2
. The drugs most commonly used for 
dyslipidemia are statins and fibrates.  Though the therapy may be started with 
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either statin or fibric acid derivatives, ultimately most of these patients require both 
the drugs or some other combination therapy. 
             Statins & fibric acid derivatives are prescribed as fixed dose formulation or 
the patients take both these drugs separately at the same time. Statins are known to 
cause myopathy & hepatotoxicity 
3
. Fibric acid derivatives also cause myopathy 
syndrome 
4
. When both the drugs are combined together, the incidences of adverse 
effects are higher & the patients may avoid taking drugs. 
             Hence it was decided to conduct the study, where a statin namely 
atorvastatin 10 mg given on one day & fibric acid derivative namely fenofibrate 
160 mg given on next day, that is atorvastatin 10 mg & fenofibrate 160 mg given 
on alternate days & the results are compared with both drugs given together daily. 
          Certain drugs are given as fixed dose combination. The purpose is to reduce 
the dose of individual drug, enhance the therapeutic benefit and to minimize the 
adverse effect. But in our study it is designed to find out the same benefits are 
achieved by giving the drugs (atorvastatin & fenofibrate) separately & on alternate 
days. In alternate day therapy, the total dosage of atorvastatin 10 mg & fenofibrate 
160 mg is only half of both the drugs given together daily. So this study is 
conducted to assess the benefit & risk of alternate day therapy with daily therapy. 
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REVIEW OF LITERATURE 
DYSLIPIDEMIA 
            Dyslipidemia is a major cause for the development of ischemic diseases. 
Dyslipidemia is the disorder of the metabolism of lipoproteins. They manifest as 
one or more of the following 
5
- 
 Increased TC levels. 
 Increased TG levels. 
 Increased LDL-C levels. 
 Decreased HDL-C levels. 
 
  
                                Courtesy – Medindia.net 
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HYPERLIPIDEMIA & ATHEROSCLEROSIS 
           Atherosclerosis is the pathologic process by which cholesterol & 
calcium plaque accumulates within the arterial wall. Atherosclerosis was 
first described on autopsy 
6
,as the term “athero” means porridge & 
“sclerosis” means scarring . 
The first person to demonstrate the role of cholesterol in the development of 
atherosclerosis was Nikolai N. Anichkov (1885–1964). His classic 
experiments in rabbits in 1913 opened the path for our current understanding 
about the importance of cholesterol in CVS diseases 
7
.  
  
Dr.Nikolai.N.Anichkov (courtesy – Anichkov Family) 
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             The discovery by Brown and Goldstein of LDL receptors and the 
mechanisms of cholesterol metabolism permitted testing of “cholesterol 
hypothesis” (mechanical injury would increase the infiltration of plasma 
components into the artery) with efficient pharmacologic & genetic tools in 
our day to day life 
7
. 
                 Myocardial infarction & angina pectoris are mainly due to 
atherosclerosis of the coronary arteries. Similarly, atherosclerosis of the 
arteries supplying the CNS often provokes stroke & transient ischemic 
attack
8
. In the peripheral circulation, atherosclerosis leads to gangrene & 
intermittent claudication which can jeopardize limb viability. Mesenteric 
ischemia may occur due to splanchnic circulation involvement. It can also 
affect the kidneys either directly (e.g., renal artery stenosis) or as an 
important site of atheroembolic manifestation 
8
. 
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Epidemiology 
            In the western world, atherosclerosis leads as the major cause of 
death & serious morbidity. The WHO has predicted, that in near future it 
will also become the leading cause of mortality in the entire world 
6
. The 
total number of peoples dying from cardiovascular disorders is about 30% of 
all deaths worldwide 
9
. Also, when the burden of disease is measured as 
DALYs lost the increasing global impact is about 25% of the DALYs lost
10
. 
A rapid increase in the burden of coronary artery disease is now emerging, 
partly because of longer life expectancy with many more people in CHD 
prone ages but also because age-specific CHD mortality rates are 
accelerating
11
. 
           In India, it is estimated that there were approximately 46.9 million 
patients during the year 2010
10
. Premature deaths seem to be more common 
in India as 52% of the CAD deaths occurred below 65 as compared to 22% 
in developed countries 
12
. On Comparing with other countries, India has the 
greatest loss in potentially productive years of the life due to the 
atherosclerosis associated diseases, with a high mortality in middle aged 
adults mainly in urban areas. During the past 30 years, Coronary artery 
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disease rates increased twice in India, whereas reduced to half in most of the 
developed countries like US
13
.  
          Incidence of CAD has been increased in urban areas than rural areas 
reflecting the acquisition of risk factors like alcoholism, tobacco consuming, 
unhealthy diet, obesity, etc…  In one study, the prevalence of ischemic heart 
diseases among adults (based on clinical & ECG criteria) was estimated at 
96.7 per 1000 population in the urban & 27.1 per 1000 in rural areas 
10
. 
There is significantly higher body mass index in urban peoples than rural 
peoples (24 Vs 20 in male; 25 Vs 20 in female) in India. An increased rate of 
abdominal obesity is seen among the urban population. Urban males are 
having waist hip ratio of 0.99 Vs 0.95 in rural males 
13
. 
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RISK FACTORS FOR ATHEROSCLEROTIC DISEASE 
14
 
    Non Modifiable Factors 
 Age  (> 45 years in males ; > 55 years in females) 
  H/O of premature CHD in the family. 
 Family H/O Hereditary Dyslipoproteinemias 
 Ethnic Group (migrants moving from one community to another) 
 Established Vascular disease  (intermittent claudication is a risk factor for 
both stroke & aortic aneurysm) 
Major Modifiable Risk Factors 
 Current smoking (smoking within past one month). 
 HT ( BP ≥ 140/90 or usage of drugs to treat hypertension, irrespective of 
BP) 
 Reduced HDL  (< 40 mg/dl in males & < 50 mg/dl in females) 
 Sedentary life style. 
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Other Factors 
 Type 2 Diabetes Mellitus. 
 Obesity.  
 Homocysteinemia. 
 Psychosocial Environment. 
 Exogenous Estrogens. 
 Type A personality. 
 Alcohol. 
 Infection (Chlamydia Pneumoniae) 6 
 
 
 
 
 
 
10 
 
HISTOPATHOLOGY 
Normal Artery 
          The healthy artery consists of 3 histologically distinct layers. Tunica intima 
is the innermost layer which surrounds the lumen, with a single layer of endothelial 
cells
15
. The Tunica media surrounding the intima consists of a single layer of 
vascular smooth muscles. The tunica adventitia is a connective tissue layer which 
encloses tunica media of all arteries .It also contains nerves and blood vessels.  
Atherosclerotic vessel 
             Atherosclerosis is a disease mainly affecting the intimal layer of elastic 
arteries. Most often involved in the order of frequency are coronary, carotid, 
cerebral, aorta & renal arteries. The lower limb arteries are also vulnerable 
6
. But, 
the internal mammary artery is almost always spared, making it invaluable for 
CABG surgery. Atherosclerotic lesions develop for many years & pass through 
several overlapping stages.  The earliest lesion histologically, is lipid laden 
macrophage foam cells &T lymphocytes which are accumulated in sub endothelial 
position, called fatty streak. On gross examination they are visible as yellow 
streaks which follow the direction of blood flow
16
. 
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Atheromatous Plaque 
 
(Courtesy- Medindia.net) 
Pathophysiology of atherosclerosis 
 
(Illustration from Libby P: Inflammation in Atherosclerosis. Nature 202) 
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PATHOGENESIS 
17
 
The important steps involved in atherosclerotic process are - 
 Endothelial injury 
 Lipoprotein deposition 
 Inflammatory reaction 
 Fibrous cap formation 
Injury of endothelial cell: This is the initial factor which starts the process 
of atheromatous plaque formation. As the endothelium is regularly exposed 
to blood circulation, the toxin like tobacco& diabetes, dyslipidemia can 
result in damage.  The continuous physical force acting upon the 
endothelium plays a main role in the atheromatous plaque that occurs mostly 
at bifurcations of the left anterior descending artery & left main coronary 
artery.  
Lipoprotein deposition: When there is injury in endothelium, the 
lipoprotein molecules enters where they are modified by oxidation (via 
oxidizing enzymes) or glycation (diabetes). This lipoprotein which is 
modified becomes inflammatory & is ingested by macrophages forming 
foam cells in the arterial wall. 
13 
 
Inflammatory reaction: The LDL modified becomes antigenic & starts 
attracting the inflammatory cells into vessel wall. The inflammatory 
mediators are released after the injury of endothelium, which further 
increases the leukocyte recruitment.  
Smooth muscle cell cap: These cells slowly migrate to the plaques’ surface 
forming fibrous cap. Thick capped atherosclerotic plaque is stable, but thin 
capped are more prone to rupture or erosion leading to thrombosis.  
             Inspite of obstructing the blood flow, the atherosclerotic plaque can 
also rupture leading to vessel thrombosis & arterial aneurysm. 
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 SECONDARY CAUSES OF DYSLIPIDEMIA
18
 
S.No DISORDER MAJOR LIPID EFFECT 
1. Diabetes Mellitus Triglyceride > Cholesterol; low HDL 
2. Alcohol use Triglyceride > Cholesterol 
3. Contraceptive usage Triglyceride > Cholesterol 
4. Nephrotic syndrome  Triglyceride > Cholesterol 
5. Estrogen use Triglyceride > Cholesterol 
6. Glucocorticoid excess Triglyceride > Cholesterol 
7. Obstructive liver disease Cholesterol > Triglyceride 
8. Hypothyroidism Cholesterol > Triglyceride 
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PHASES IN PROGRESSION OF ATHEROSCLEROSIS 
 
(Courtesy- Nicole K. Brogden, PharmD, University of Kentucky HealthCare, Lexington) 
 
16 
 
ATP III Guidelines for Lipid Profile19  
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PLASMA LIPOPROTEIN METABOLISM 
                 Lipoproteins are macromolecular assemblies which contains lipids & 
proteins. TGs, esterified and free cholesterol, phospholipids are the lipid 
constituents
20
. 
                 Lipids are sparingly soluble or insoluble molecules which are needed for 
biogenesis of membrane & maintenance of its integrity
21
. The protein components 
(apolipoproteins) give structural integrity to the lipoproteins, which may function 
as ligands in lipoprotein receptor interactions or as cofactor in enzymatic processes 
that regulate lipoprotein metabolism 
20
. 
18 
 
 
Structure of Lipoprotein Particles 
              
         Lipoproteins are microscopic spherical particles about 7-100 nm in 
diameter
22
. In all the spherical lipoproteins, the water insoluble TGs, cholesteryl 
esters constitutes the core components & the water soluble, more polar 
apoproteins, unesterified cholesterol &phospholipids  forms the surface 
components.   
 
19 
 
CHYLOMICRONS 
                    Chylomicrons are the largest plasma lipoproteins which are 
synthesized from the fatty acids of dietary TGs & cholesterol which is absorbed 
from the intestine by epithelial cells. Intestinal cholesterol and plant sterol 
absorption is mediated by the NPC1L1protein that appears to be the target of 
cholesterol absorption inhibitor
20
. Triglyceride synthesis is regulated by the 
diacylglycerol transferase in many tissues. After their synthesis in ER, triglycerides 
are transferred by the TG transfer protein to the place where newly synthesised 
apoB-48 is present to form chylomicrons. 
                        The apolipoproteins of chylomicrons includes that are produced by 
intestinal epithelial cells (apoB-48, apoA-I, IV), and that acquired from HDL 
(apoE, apoC-I, II, III) after chylomicrons have been secreted into the lymph & 
enter the plasma.  Apo B48 which is synthesized only by the intestinal epithelial 
cells is unique to Chylomicrons. 
                   ApoB48 lacks the portion of sequence of apoB100 which allows apoB-
100 binding to the LDL receptor, so that apoB-48 primarily function as a structural 
component of chylomicrons. Dietary cholesterol is esterified by the ACAT-2 
23
.  
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              ACAT-2 is present in the intestine & liver, where the free cholesterol is 
esterified before the chylomicrons & VLDL are assembled. It also regulates the 
absorption of dietary cholesterol in the intestine & thus forms a potential 
pharmacological target for decreasing blood cholesterol levels. 
            After entering into the circulation through thoracic duct, CMs are initially 
metabolized at the capillary luminal surface of tissues which synthesize LPL, TG 
hydrolase. These tissues include adipose tissue, lactating breast, skeletal and 
cardiac muscle.  
               As the triglycerides are hydrolyzed by LPL, the resulting free fatty acids 
are utilized by the adjacent tissues. The interaction of chylomicrons & LPL 
requires apoC-II as a cofactor
24
.  
             The absence of functional LPL or apoC-II prevents the hydrolysis of 
triglycerides in CMs & leads to severe hypertriglyceridemia & pancreatitis during 
childhood & infancy (chylomicronemia syndrome) 
24
. The plasma concentration of 
CMs can be primarily controlled by dietary fat consumption reduction. 
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Chylomicron Remnants 
                  After lipoprotein lipase mediated removal of most of the dietary TGs, 
the CM remnants containing all of the dietary cholesterol, are detached from the 
capillary vessel surface & the liver removes them from circulation. Firstly, apo E 
sequesters the CM remnants with the heparan sulfate proteoglycans interactions & 
are processed by the hepatic lipase enzyme. Next, the remnant uptake is mediated 
by apo E by interaction with LRP
25
.  
                LRP is important in the lipid metabolism, because it is the backup 
receptor which is responsible for the uptake of apoE-enriched remnants of CMs & 
VLDL.  During the initial hydrolysis of chylomicron triglycerides by Lipoprotein 
Lipase, apoA-I & phospholipids are shed from the chylomicrons surface & remain 
in the plasma. This is one mechanism by which nascent HDL is generated. 
Chylomicron remnants are not precursors of LDL, but the dietary cholesterol 
delivered by CM remnants to the liver enhances the plasma LDL levels.  
22 
 
 
Major Pathways involved in the metabolism of Chylomicrons 
             
                   VERY LOW DENSITY LIPOPROTEINS (VLDL) 
VLDL is synthesized in the liver when TG production is stimulated by the raised 
flux of FFA or the de novo production of fatty acids by the liver. VLDL particles 
size about 40 to100 nm in diameter and are larger to form plasma turbidity. 
23 
 
               Liver synthesizes apoB-100, apoC-I, II, III, apoE and incorporates into 
VLDL
26
. The newly produced apoB-100 is degraded by the liver cells, when the 
TGs are not available to form VLDL.Triglycerides are synthesized in the ER & are 
transferred to the site in the ER by MTP, where newly formed apoB-100 is 
available to synthesize precursor VLDL. 
            Very low density lipoprotein is then catabolized by Lipoprotein Lipase in 
capillary beds. As the TG hydrolysis is completed, the VLDL remnants are 
released from capillary endothelium and it reenters the circulation. ApoB-100 
contains small VLDL and IDL (half life of <30 mins), have 2 potential fates.   
             About 40-60% is cleared by the liver from the plasma via interaction with 
LDL receptors & LRP. LPL & hepatic lipase convert the remaining IDL to LDL by 
removing the additional TGs. The apoA-V, C apoproteins and apoE redistribute to 
HDL.   ApoE plays a major role in the metabolism of TG-rich lipoproteins (CM, 
chylomicron remnants, VLDL & IDL). 
               About 50% of the apoE in the plasma of fasting subjects is associated 
with triglyceride-rich lipoproteins, and the other 50% is a constituent of HDL. 
About 75% of the apoE in plasma is synthesized by the liver. Brain and 
24 
 
macrophages synthesize the rest. In transgenic mice, over expression of apoE by 
macrophages prevents hypercholesterolemia-induced atherogenesis 
LOW DENSITY LIPOPROTEIN 
                   In the circulation, virtually all of the LDL particles are derived from 
VLDL. The LDL particles have t½ of 1.5-2 days, which is the reason for the raised 
plasma level of LDL. In persons without hyperlipaemia, 2/3
rd
 of plasma cholesterol 
is present in the LDL. 
               LDL receptors primarily mediate the plasma clearance of low density 
lipoprotein particles. The most common cause of Autosomal dominant 
hypercholesterolemia involves mutations of the LDL receptor gene. Greater than 
900 mutations of the LDL receptor gene have been found to be associated with 
defective or absent LDL receptors which may lead to Familial 
hypercholesterolemia
27
. 
               The primary apolipoprotein of LDL is ApoB-100, which acts as the 
ligand binding LDL to its receptor. 3000-3700 residues in the carboxyl-terminal 
sequence are essential for binding. A mutation in this region affects binding and 
causes Autosomal dominant hypercholesterolemia (familial defective apoB-100).  
25 
 
                 Liver expresses a greater complement of LDL receptors and helps in 
removing 75% of all LDL from plasma.  By manipulating the liver LDL receptor 
gene expression, plasma LDL levels can be effectively modulated. Thyroxine & 
estrogen raises LDL receptor gene expression thereby lowers LDL
27
. 
               Regulation of LDL receptor expression is by which cells regulate their 
free cholesterol content. This regulatory process is mediated by transcription 
factors such as SREBPs and Scap 
28
.   
             Scap is both a sensor of CH content in the endoplasmic reticulum & an 
escort of SREBPs from the ER to Golgi apparatus. LDL becomes atherogenic by 
oxidation
29
, a required step for LDL uptake by the scavenger receptors of 
macrophages which leads to foam-cell formation in arterial lesions.2 scavenger 
receptors (SRs) involved are SR-AI/II & CD36.  By knocking out either receptor in 
transgenic mice retards the uptake of oxidized LDL by macrophages. Expression 
of the 2 receptors is different.SR-AI/II expressed more in early atherogenesis, and 
CD36 expressed greater as foam cells during disease progression. 
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HIGH DENSITY LIPOPROTEIN (HDL) 
                  ApoA-I is the major HDL apoprotein.The plasma concentration of apo 
A-I forms the more powerful inverse predictor of CHD risk
30
. For normal 
production of HDL, ApoA- I synthesis is essential. Mutations in the apoA-I gene 
cause HDL deficiency leading to accelerated atherogenesis. The over expression of 
apoA-I in transgenic mice protects experimentally induced atherogenesis. 
                HDL is protective lipoprotein which decreases the CAD risk. This 
protecting effect is because of HDL participating in the reverse cholesterol 
transport (excess cholesterol obtained from cells is excreted, by transferring to the 
liver).HDL also protects atherogenesis by mechanisms which are not directly 
related to reverse cholesterol transport such as putative anti-inflammatory, anti-
oxidative, platelet anti-aggregatory, anticoagulant & profibrinolytic activities
31
.          
Lp (a) 
                Lipoprotein (a) mainly contains an LDL particle that has a 2
nd
 apoprotein 
along with apoB-100 
32
. It is attached by means of one disulfide bond, to apoB-
100.It never functions as a lipid-binding apoprotein. A structural relation of apo (a) 
is seen with plasminogen .It is atherogenic as it interferes with fibrinolysis of 
thrombi on surface of plaque. 
27 
 
CHARACTERISTICS Of PLASMA LIPOPROTEINS
33 
Lipoprotein 
Class 
Major lipid 
constituent 
TG:Choles
terol ratio 
Significant 
apoproteins 
Mechanism of 
catabolism 
ChyloMicron & 
Remnants 
Dietary TG 
&Cholesterol 
10:1 B48,E,AI,AIV, 
CI,CII,CIII 
TG hydrolysis by 
LPL,remnant 
uptake by liver 
mediated by apoE 
VLDL Endogenous or 
liver TG 
5:1 B100,CI, 
CII,CIII,E 
TG hydrolysis by 
LPL 
IDL Cholesteryl 
esters &   
Endogenous 
TGs  
1:1 B100,E,CII, CIII 50% converted to 
LDL, 50% apo E 
mediated uptake 
by liver 
LDL Cholesteryl 
esters 
Not 
significant 
B100 Apo B100 
mediated uptake 
by LDL receptor 
HDL Phospholipids, 
Cholesteryl 
Not 
significant 
AI,AII,E,CI,CII,
CIII 
Transfer of 
Cholesteryl ester 
28 
 
esters to VLDL & LDL 
Lp(a) Cholesteryl 
esters 
Not 
significant 
B100,apo (a) Unknown 
 
LABORATORY INVESTIGATIONS
34
 
 Routine blood & urine examination 
 Fasting lipid profile 
 Random blood sugar 
 Blood urea & Serum creatinine 
 Liver function test, CPK 
MANAGEMENT OF DYSLIPIDEMIA
35
 
Non Pharmacological  
 Restrict dietary saturated fat and cholesterol. 
 By taking 3 times /day, the plant sterols & esters reduces LDL -C by 10%. 
 Exercise.  
 Weight reduction. 
29 
 
PHARMACOLOGICAL 
 Competitive HMG -CoA reductase inhibitors (Statins): 
Simvastatin, pravastatin, lovastatin, atorvastatin, rosuvastatin, pitavastatin. 
 Bile Acid Sequestrants (Resins):  
Cholestyramine, colesevelam, colestipol. 
 Lipoprotein lipase activators (PPARα activators -Fibrates): 
 Clofibrate, Fenofibrate, Gemfibrozil, Bezafibrate. 
 Lipolysis & TG synthesis inhibitor: 
 Nicotinic Acid 
 Sterol absorption inhibitor:  
Ezetimibe. 
 Omega 3 fatty acids (Fish oils) 
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STATINS 
                  The statins are the most effective & best tolerated drugs routinely used 
to treat dyslipidemia. These drugs are the competitive HMG Co A reductase 
inhibitors, that catalyses the rate limiting step in cholesterol synthesis. 
             
HISTORY 
              Statins were isolated from the fungus, Penicillium citrinum. Endo & 
colleagues
36
identified stains as cholesterol biosynthesis inhibitors in 1976. 
Subsequent studies by Brown and Goldstein established that statins act by 
inhibiting HMG CoA reductase. The first statin studied in humans was compactin 
renamed as mevastatin. Lovastatin was the first statin approved for use in humans 
(formerly known as mevinolin), that was isolated from Aspergillus terrus. 
Pravastatin & simvastatin were chemically modified derivatives of lovastatin. 
Atorvastatin, fluvastatin, rosuvastatin, pitavastatin were synthetic compounds. 
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ATORVASTATIN 
CHEMICAL STRUCTURE
37
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CHEMICAL NAME 
37
 
[R-(R*, R*)]- 2-(4- Fluor phenyl)-γ, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-
4-[(phenyl amino) carbonyl]-1H-pyrrole-1-heptanoicacid calcium salt 
Mol. Formula- C33H35Ca2FN2O5 
Mol. Mass - 558.64 g/mol 
 
          Physical Properties
37
 
                It is an off-white crystalline powder, which is synthesised chemically. 
This compound is stable with no marked effect of heat, common solvents or pH. It 
is insoluble in water pH < 4, very slightly soluble in phosphate buffer and 
acetonitrite & easily soluble in methanol, tetrahydrofuran. Upon exposure to 
sunlight the atorvastatin readily decomposes into 3 major byproducts – lactam 
isomers, phenantherenes and diketoepoxide. 
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Mechanism of Action 
            The statins reduces LDL-C levels by competitively inhibiting HMG CoA 
reductase enzyme. By decreasing the conversion of HMG CoA to mevalonate, they 
block the rate limiting step. 
           Statins reduces the cholesterol level by blocking the hepatic cholesterol 
synthesis .This leads to raised expression of LDL receptor gene. Due to the 
decreased free cholesterol content within the liver cells, the membrane bound 
SREBPs are sequestered by the protease enzyme & are translocated to the nucleus. 
The transcription factors then bind with the SRE of the LDL receptor gene, 
enhancing the LDL receptors synthesis
38
. There is also reduction in LDL receptors 
degradation.  
           The major metabolites of atorvastatin are the para- & ortho-hydroxy 
metabolites & a glucuronide conjugate of the O-hydroxy metabolite 
37
.The para- 
and ortho-hydroxy metabolites are active showing the blocking effects towards 
HMG CoA reductase in vitro human liver micro enzymes. About 70% of the HMG 
CoA reductase inhibition of atorvastatin has been attributed to its active 
metabolites. 
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Mechanism of Action of Atorvastatin 
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Statins on TG levels 
            TG > 250 mg/dl are substantially decreased by statins and the percentage 
reduction obtained is same as that of LDL cholesterol. The hypertriglyceridemia 
patients who take higher doses of Atorvastatin experience a 35-45% decrease in 
fasting TG levels
39
. 
 
Statins on HDL-C levels 
                 In patients with increased LDL levels & gender appropriate HDL-C 
levels, an increase in HDL of 5-10% was found irrespective of  the dose. However, 
in patients with decreased HDL-C (<35 mg/dl) statins may differ in their effects by 
increasing the HDL-C & apoA-I levels
40
.  
 
Statins on LDL-C levels 
               Depending on the type and dose of statins used, they lower LDL-C by   
20-55%. Greater reduction of LDL-C noted at higher dose of Atorvastatin.  These 
36 
 
drugs are effective in almost all patients with elevated LDL-C levels except those 
with homozygous familial hypercholesterolemia because both alleles of the LDL 
receptor gene code for dysfunctional LDL receptors. LDL-C is reduced by 
about6% with each dose doubling 
41
. Maximal effect on plasma lipid levels are 
reached within 7-10 days. Statin therapy does not cause reduction of LP (a) levels. 
 
POTENTIAL CARDIO PROTECTIVE EFFECTS 
The Non Lipid Roles of Statins are – 
  Endothelial function  Treatment with statin induces endothelial synthesis 
of the NO, which leads to enhanced endothelial function that is independent 
of changes in plasma cholesterol levels. 
 
 Statins & Plaque stability  Statins act by inhibiting monocyte infiltration 
into the vessel wall & macrophage production of matrix metalloproteinase in 
vitro. They also inhibit smooth muscle cells proliferation & enhance 
apoptosis. 
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 Statins & Inflammation  They have an anti inflammatory role. They 
reduce the risk of CHD & CRP levels. Metabolic syndrome & body weight 
are associated with raised levels of highly sensitive CRP 
42
. 
 
 
 Statins & Coagulation  The important evidence of non lipid lowering 
effect of a statin is reduction in venous thromboembolism .They decrease 
platelet aggregation & deposition of thrombi. They also have variable effects 
on the fibrinogen levels.  
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ABSORPTION, METABOLISM, EXCRETION 
              The intestinal absorption of the statins is 30-85%, after oral 
administration. Maximum plasma concentration occurs within 1-2 hours.  
Atorvastatin is administered in the β-hydroxy acid form which inhibits HMG 
CoA reductase. Atorvastatin has extensive first pass metabolism, mainly 
mediated by OATP1B1 
43
.  
              Its absolute bioavailability is 14% & the systemic availability of 
inhibitor activity is about 30%. The decreased systemic availability is due to 
high presystemic clearance in GI mucosa & liver. In the plasma, >95% of 
statin & their metabolites are protein bound. 
              The t½ of atorvastatin is ~ 20 hours. This longer t½ of atorvastatin 
contributes to their greater cholesterol lowering efficacy
43
. Primary excretion 
is in the hepatic circulation & atorvastatin is metabolised by cytochrome P 
450 3A4 in the liver, subsequently eliminated in faeces 
37
. 
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ADVERSE EFFECTS & DRUG INTERACTIONS 
Hepatotoxicity: 
                The post marketing surveillance studies of statin showed a raise in 
liver transaminase levels > 3 times the upper normal limit (incidence > 1%). 
This incidence appeared to be dose related. In placebo controlled outcome 
clinical trials, the incidence of 3 fold rise in transaminases was 1-3% 
compared to placebo when 10-40 mg dose of atorvastatin, pravastatin, 
simvastatin were used
44
. It is therefore essential to measure ALT before & 
after study when clinically indicated. 
                Observational studies & a prospective trial suggests that the 
transaminase elevations in patients with nonalcoholic fatty liver disease & 
hepatitis C are not at risk of statin induced hepatotoxicity 
45
. This is 
important, as many insulin resistant patients are affected by nonalcoholic 
fatty liver disease & have rise in transaminases.  
              Insulin resistant patients are associated with increased CVD risk 
seems to be benefiting from statins (Cholesterol Treatment Trialists’ 
40 
 
Collaborators, 2008). It is reassuring that these patients with elevated 
transaminases can safely take statins.     
Myopathy: 
                     The main adverse effect of statins is myopathy 
46
. The risk of 
myopathy & rhabdomyolysis rises in proportion to statin dose & plasma 
concentration. The factors inhibiting statin catabolism are associated with 
increased myopathy risk such as elderly age (> 80 yrs), renal/hepatic 
dysfunction, perioperative periods, diabetes mellitus, and hypothyroidism 
47
. 
The most common interactions are seen with gemfibrozil (38%), warfarin 
(4%), cyclosporine (4%), digoxin (5%), macrolide (3%), azole antifungals 
(1%) and others such as protease inhibitors, amiadarone, nefazadone, and 
niacin (rare) 
47
. 
               Gemfibrozil, the drug most commonly associated with statin 
induced myopathy, inhibits the uptake of the active hydroxy forms of statins 
into hepatocytes by OATP1B1. Other fibrates, especially fenofibrate do not 
interfere with glucuronidation of statins and pose less risk of myopathy 
when combined with statin therapy. When niacin is administered with statin, 
41 
 
myopathy is caused by an enhanced inhibition of skeletal muscle cholesterol 
synthesis.    
            Drugs that interfere with statin oxidation are those metabolised 
primarily by CYP3A4 which includes erythromycin, itraconazole, 
cyclosporine, nefazadone (anti depressant), protease inhibitors and 
amiadarone
48
. These interactions are due to the increased plasma 
concentrations of statins and their active metabolites. Atorvastatin is 
primarily metabolised by CYP3A4 & 3A5.  
              Despite the rarity of ten-fold elevations of CK, many patients 
complain of myalgia while taking statins. It is unclear if such myalgias are 
caused by taking statins. Replacing Vit D in patients with a Vit D deficiency 
reportedly reduces statin related myalgias & improves statin tolerance.  It is 
potentially significant, because Vit D deficiency is associated with 
myopathy, insulin resistance & increased incidence of CVD. 
Pregnancy & Lactation:  The safety of statins during pregnancy has not 
been established. During child bearing years, while taking statins are advised 
to take better contraception. Nursing mothers better to avoid taking statins. 
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THERAPEUTIC USES 
Lipid lowering effect 
                  Cholesterol synthesis is maximal in between midnight & 2 am. 
As atorvastatin has a long t½, it can be administered at any time of the day 
with minimal dose of 10 mg and maximal dose of 80 mg per day
49
. It is 
marketed combined with CCB (amlodipine) for patients with HT, angina and 
hypercholesterolemia. The drug to be initiated with 5-10 mg daily, 
increasing stepwise, if needed, until myopathy incidence is better defined. If 
combined with gemfibrozil, the dose must not exceed 10 mg. 
                    The choice of statins is based on efficacy (reduction in LDL-C) 
and cost. The documented safety records of the statins should be considered, 
mainly in younger patients while starting therapy. A baseline determination 
of ALT and test is repeated at 3-6 months interval. If ALT is normal, then it 
can be done once every 6-12 months. CK is not routinely measured, unless 
the patient is on treatment with drugs that enhances the risk of myopathy
49
. 
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Statins in combination with other lipid lowering drugs 
             Statins combined with cholestyramine & colestipol, produces 20-
30% greater reductions in LDL-C than statins alone. Niacin also enhances 
the statin effect, but myopathy occurrence rises when doses > 25% of 
maximum are used with niacin. Fenofibrate (least to interfere with statin 
metabolism) appears to be the safest fibrate to use with statins
50
. 
Combination therapy with resins, niacin and statins can reduce LDL upto 
70%. 
44 
 
 
Cholesterol Transport in the Tissues, With Sites of Action 
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FIBRATES (PPAR activator) 
 
HISTORY 
                In 1962, Thorp and Waring reported that ethyl chlorophenoxyisobutyrate 
lowered lipid levels in rats. In 1967, the ester form (clofibrate) was approved for 
use in the U.S. and became the most widely prescribed hypolipidemic drug. Its use 
declined dramatically, however, after the WHO reported that, despite a 9% 
reduction in cholesterol levels, clofibrate treatment did not reduce fatal 
cardiovascular events, although nonfatal infarcts were reduced.  
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FENOFIBRATE 
CHEMICAL STRUCTURE
51
 
 
Chemical Name  
 2-[4-(4-chlorobenzoyl) phenoxy]-2-methylpropanoic acid1-methylethylester. 
Mol.Formula            C20 H21 Cl O4   
Mol.mass                  360.831 g/mol 
Physical Properties 
51
 
                Fenofibrate is a whitish, crystalline powder that is tasteless & odourless. 
It is a fibric acid derivative, an analogue of clofibrate, which is synthesized 
chemically. It differs from clofibrate by the substitution of a chlorobenzoyl ketone 
group for a chlorine atom. 
47 
 
MECHANISM OF ACTION 
                       The effects of fibrates on plasma lipid levels are due to their 
interaction with peroxisome proliferator-activated receptors (PPARs) 
52
. There are 
3 PPAR isotypes (α, β, γ). They bind to PPAR, which is expressed mainly in the 
hepatocytes & brown adipose tissue and to a smaller extent in kidney, heart & 
skeletal muscle. They reduce TGs through PPAR-mediated stimulation of fatty 
acid oxidation, raised LPL synthesis & decreased apo C III expression. Fibrates 
increases HDL-C mainly by PPAR stimulation of apoA-I & apoA-II. Among all 
fibrates fenofibrate is more effective in increasing HDL levels. 
                    LDL levels are unchanged or fall in, especially for those whom TG 
levels are not increased or who are taking a 2
nd
-generation agents like fenofibrate, 
bezafibrate, or ciprofibrate. The decrease in LDL levels may be due to changes in 
the cholesterol and triglyceride contents of LDL that are mediated by CETP. 
                 Most of the fibrates have potential antithrombotic effects, like blocking 
coagulation & enhancing fibrinolysis
52
. These effects could alter the cardiovascular 
diseases unrelated to any of the hypolipidemic activity. 
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Effects on Lipoprotein Levels 
                     In patients with mild hypertriglyceridemia (TG < 400 mg/dL), 
treatment with  fibrate reduces TG levels up to 50% & rises the HDL-C levels by 
15%. Fenofibrate lowers VLDL level, but also reduce LDL levels by 15-20%. In 
marked hypertriglyceridemia (400-1000 mg/dL), a similar fall in TGs occurs, but 
LDL-C increases by 10-30%.  
                     Usually fibrates are the treatment of choice for severe 
hypertriglyceridemia & chylomicronemia syndrome. The primary therapy is to 
avoid alcohol & fat rich diet. Fibrates act by increasing triglyceride clearance and 
reducing hepatic TG synthesis. In chylomicronemia syndrome patients, 
maintenance therapy with fibrate and a low-fat diet keep TG levels < 1000 mg/dL 
and hence prevent the episodes of pancreatitis
52
. 
49 
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ABSORPTION, FATE & EXCRETION 
              These drugs are absorbed rapidly & effectively (>90%) when taken along 
with food. The ester bond is hydrolyzed rapidly & the peak plasma levels are 
reached within 1-4 hours.  
                Fenofibrate is completely metabolised to fenofibric acid. More than 95% 
are bound exclusively to albumin. The plasma half life of fenofibrate is 20 hours 
.This drug is widely distributed in the body & the concentration in kidney, liver & 
intestine exceeds the plasma level.  
              The fibrates are excreted mainly by glucuronide conjugation; about 60-
90% of oral dose administered is excreted in the urine, with lesser amount in the 
feces. Excretion is affected in renal failure
52
. The fibrates usage is contraindicated 
in renal failure patients.  
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THERAPEUTIC USES 
                Fenofibrate is available in 2 different formulations. The first preparation 
developed is the dimethyl ethyl ester of fenofibrate, which is poorly water soluble 
& poorly absorbed. After uptake by the liver, this is hydrolyzed to form fenofibric 
acid (active moiety). Recently, a choline salt of fenofibric acid which is highly 
soluble in water & readily absorbed was developed. The effects of both 
formulations are similar with respect to changes in plasma lipid concentrations
53
. 
Choline fenofibrate is indicated for combination with statins.  
                Fibric acid derivatives are the drug of choice for treating patients with 
type III hyperlipoproteinemia and severe hypertriglyceridemia (TG >1000 mg/dL) 
who are at risk for pancreatitis. Fibrates have an important role in patients with 
raised TG & decreased HDL levels associated with metabolic syndrome or type 2 
DM.  When fibrates are used in these patients, the LDL levels to be monitored; if 
LDL levels increases, then a low dose of a statin may need to be added. Many 
physicians now give treatment to such patients initially with statin (Heart 
Protection Study Collaborative Group, 2003) and then add a fibrate, based on the 
reported benefit of fibrate therapy. Careful monitoring for myopathy is needed 
when this combination is used. 
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ADVERSE EFFECTS & DRUG INTERACTIONS 
                     GI upsets occur in about 5%. Rash, urticaria, hair loss, myalgias, , 
headache, impotence, fatigue and anemia are reported infrequently. Minimal 
elevations in liver transaminases and alkaline phosphatase also have been reported. 
                    Fibrates have been found to enhance the activity of oral 
anticoagulants, by displacing them from their albumin binding sites. So, it is 
essential to carefully monitor the PT and reduce the dose of anticoagulant before 
starting treatment with fibrate. 
                  Myopathy syndrome may occur in patients on fenofibrate. To diminish 
this risk, it is better to reduce doses of statin when combined with fibrate. Several 
drug interactions may be the reason for this adverse response. Patients receiving 
combination therapy should be advised to be aware of these symptoms & to be 
followed up at every 3-month intervals. Fenofibrate undergoes glucuronidation by 
enzymes which are not associated with statin glucuronidation.  
               Hence, fenofibrate + statin have less possibility to cause myopathy. All of 
the fibrates increase the lithogenicity of bile. They should be avoided in renal 
patients. Fibrates are contraindicated in children & pregnant women. 
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AIM & OBJECTIVES 
 
AIM: 
             To study the efficacy of alternate day therapy of atorvastatin 10 mg  & 
fenofibrate 160 mg on plasma lipid profile  and to compare it with daily therapy of  
atorvastatin 10 mg  & fenofibrate 160 mg . 
 
OBJECTIVES:   
(1) To see if the alternate day therapy is equally efficacious or not 
when compared to daily therapy. 
(2) To see if the alternate day therapy has better side effect profile 
when compared to daily therapy. 
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MATERIALS & METHODS 
SCREENING & ENROLLMENT 
                    After obtaining approval from the Institutional Ethics committee the 
study was conducted. Details of the study were explained to the patients who 
attended the outpatient section of Department of Medicine & Diabetology in 
Government Stanley Hospital, Chennai. Written informed consent was obtained in 
their native language, from those who were willing to participate in this study. 
                    The patients were screened for dyslipidemia & the patients who suit 
our inclusion and exclusion criteria were selected for the study. The participants of 
this study were randomized into 2 groups with 30 patients allotted in each group. 
                    After clinical examination, participants were investigated for 
hematological & biochemical tests. The baseline demographic characters were 
recorded including patients name, age, sex, outpatient number, occupation & 
address. 
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STUDY DESIGN:  Prospective, Randomized, Open label, comparative, case     
control study. 
STUDY CENTRE:  Out Patient section, Dept of Medicine & Diabetology, 
                                   Government Stanley Hospital, Chennai-01 
STUDY PERIOD: 1.12.2012 to 30.11.2013 
 DURATION OF STUDY: 6 weeks for each patient. 
SAMPLE SIZE:  60 patients (30 patients in each group) 
DRUGS USED IN THE STUDY: 
                  Fenofibrate 160mg  Fenobate 160(East west Pharmaceuticals)     
                  Atorvastatin 10 mg  (Hospital supply) 
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SELECTION CRITERIA:  (For both groups) 
 INCLUSION CRITERIA: 
1) Both male & female patients. 
2) Age between 45 – 55 years. 
3) Newly diagnosed cases of dyslipidemia. 
4) Patients with elevated levels of LDL, VLDL, Triglycerides & 
total cholesterol  as follows
19
 - 
a) Patients with elevation of Total cholesterol  >200 mg/dl. 
b) Patients with elevation of Triglycerides  > 200 mg/dl.  
c) Patients with HDL < 40 mg/dl. 
d) Patients with elevation of LDL >100 mg/dl. 
e) Patients with elevation of VLDL >30 mg/dl  
5) Patients with Diabetes Mellitus (Type 2) and dyslipidemia. 
6)  Patients with Hypertension and dyslipidemia. 
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EXCLUSION CRITERIA: 
 
(1) Patients with H/O primary hyperlipidemia. 
(2) Patients < 45 & > 55 years of age. 
(3) Patients with H/O MI, Cerebro vascular disease, Peripheral vascular 
disease, Hypertension with complications & other neuromuscular 
disorders. 
(4) Patients with H/o hepatic damage, smoking & alcoholism. 
(5) Patients with Thyroid dysfunction. 
(6) Patient with high level of Triglyceride alone & LDL alone. 
(7) Patients who are on antiplatelet drugs. 
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METHODOLOGY 
The selected patients were randomized into two groups namely 1 & 2, with the 30 
patients in each group. 
 
Group 1 (Control) Atorvastatin 10 mg & Fenofibrate 160 mg are given 
together at bed time daily for 6 weeks 
Group 2 (study group) Atorvastatin 10 mg at bed time on one day & 
Fenofibrate 160 mg at bed time on next day 
          
Lipid profile including Total cholesterol, LDL, HDL, TG, VLDL were done for 
both the groups at the baseline and then at the end of 2
nd
 week, 4
th
 week, 6th week 
&12
th
 week (follow up). 
 Routine investigation like Hb, blood sugar, blood urea, serum creatinine, 
SGOT,SGPT,CPK were all evaluated before & after the study.  
Patients were allowed to take medications for other associated conditions like 
Hypertension, Diabetes Mellitus.        
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Results 
Screening 
(93) 
 
 
Recruitment 
 
INCLUDED (60) EXCLUDED (33) 
DAILY REGIME 
(30) 
ALTERNATE REGIME 
(30) 
Evaluation At 2 Weeks Interval For 6weeks 
Follow Up at 12 Weeks 
Data Consolidation& Statistical Analysis 
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                    This study was conducted, to evaluate the effect of alternate day 
therapy of Atorvastatin 10 mg & Fenofibrate 160 mg on plasma lipid profile and to 
compare it with daily therapy of atorvastatin 10 mg & fenofibrate 160 mg. 
                Out of 93 patients screened, 60 patients were included in this study. 33 
patients were excluded based on Selection criteria. 60 patients were randomly 
allocated into 2 groups as Group 1 & Group 2 and treated according to the 
methodology. 
              The clinical & Laboratory investigational results obtained for both control 
and study group at the baseline & at the end of 2
nd
, 4
th
, 6
th
 and 12
th
 week (follow 
up) were analyzed statistically. The Parameters analyzed were TC, LDL, TG, 
VLDL and HDL.Biochemical parameters like Hb, RBS, Blood urea, S.creatinine, 
AST,ALT, and CPK of  both the groups were performed before & after study and 
analyzed for significant changes. 
 
 
 
61 
 
Table No: 1a Age Distribution (Mean Age) 
Group 
N Mean Std. Deviation 
Student independent ‘t’ 
test 
Control 30 50.29 2.989 t=0.09 
 P= 0.991 Study 30 50.33 3.011 
 
 
 
Figure No: 1a Age Distribution (Mean Age) 
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Table No: 1a shows 
 Mean age distribution of both control & study groups with mean age of 
50.29 in control group and 50.33 in study group. 
 Analysis done by using Student independent‘t’ test. 
 ‘p’ value – Not significant. 
 
Figure No: 1a shows  
  Bar diagrammatic representation of  mean age distribution (Table No :1a)  
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Table No: 1b Age Distribution (N (%)) 
 
Age in 
years  
Control Study Pearson Chi-square test 
N % N % 
45-50 12 40% 13 43.33%  
   χ2 =0.705 ,p=0.951 
 
51-55 18 60% 17 56.67% 
 
 
Figure No: 1b Age Distribution (%) 
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Table No: 1b shows 
 Age distribution (N (%)) in both control and study groups. 
 40% of patients in control group & 43.33% of patients in study group 
were in the age group of 45-50 years and 60% of patients in control 
group & 56.67% in study group were in the age group of 51-55 years. 
 Statistical analysis done by Pearson Chi Square Test. 
 ‘p’ value was not significant. 
 
Figure No: 1b represents 
 Bar Diagrammatic representation of Age Distribution (%) (Table No: 1b) 
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Table No .2: SEX DISTRIBUTION 
Sex Group 
Pearson   
Chi square Test Control Study 
N % N % 
MALE 17 56.7% 17 56.7%    χ2= 0.00 
  P= 1.00 FEMALE 13 43.3% 13 43.3% 
Total 30 100.0% 30 100.0% 
P ≤ 0.05  significant; P≤ 0.01highly significant; P≤0.001 very high significant. 
 
 
Figure No -2a: SEX DISTRIBUTION (Control group) 
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Figure No-2 b: SEX DISTRIBUTION (Study group) 
 
 
Table No: 2 shows 
 Sex distribution in both groups. 
 Statistical analysis done by Chi square test. 
 ‘p’ value was not significant. 
Figure No: 2a shows 
 Pie Chart diagrammatic  representation of  sex distribution in 
control group in Table No:2 
Figure No: 2b shows 
 Pie Chart diagrammatic  representation of  sex distribution in 
study group in Table No:2 
Male 
57% 
Female 
43% 
Sex Distribution Study 
Male Female
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Table No 3: TOTAL CHOLESTEROL 
 
 
GROUP N Mean(mg/dl) Std. Deviation 
‘p’ value  
 
% Reduction 
from Baseline 
TC Baseline 1 30 285.77 18.873 0.640 0 
2 30 288.13 20.046  0 
TC 2nd week 1 30 226.57 26.666 0.151 20.71 
2 30 237.23 30.038  21.45 
T C 4th week 1 30 182.97 18.314 0.158 35.97 
2 30 189.43 16.650  34.25 
TC 6th week 1 30 159.57 14.486 0.513 44.16 
2 30 161.87 12.533  43.82 
TC 12th week 1 30 152.40 15.138 0.382 46.67 
2 30 155.50 11.930  46.03 
Repeated Measures of ANOVA  
Within Groups : F= 1801.3 , P < 0.001 
Between Groups : F= 1.28 , P = 0.268 
P ≤ 0.05 significant;  P≤ 0.01 highly significant;  P≤0.001 very high significant. 
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Figure No 3: TOTAL CHOLESTEROL 
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Table No: 3 shows 
             The mean, SD and % reduction of Total cholesterol in both the groups. 
              Statistical analysis was done by using Student independent‘t’ test. 
              The mean value of TC in the control group (Group 1) was 285.77 mg/dl & 
in the study group (Group 2) was 288.13 mg/dl in the baseline (‘p’ value =0.640; 
not significant). 
             At the end of 2
nd
 week, mean value of TC in group 1 was 226.57 mg/dl & 
group 2 was 237.23(‘p’ value = 0.151; Not significant).At the end of 4th week, 
mean value of TC in group 1 was 182.97 & group 2 was 189.43 (‘p’value= 0.158; 
not significant). 
              At the end of 6
th
 week, mean value of TC in group 1 was 159.57 & group 
2 was 161.87 (‘p’value= 0.513; not significant).At the end of 12th week (Follow 
up), mean value of TC in group 1 was 152.40 & group 2 was 155.50 (‘p’value= 
0.382; not significant). 
             The % reduction from the baseline of TC at the end of 2
nd
 week was 
20.71% in group 1 & in group 2 it was 21.45%, at the end of 4
th
 week the reduction 
70 
 
was 35.97% in group 1 & 34.25% in group 2, by the end of 6
th
 week  it was 
44.16% & 43.82% and at the  follow up it was 46.67% & 46.03%  . 
         Repeated measures of ANOVA –Within groups (‘p’ value <0.001) was 
significant; between groups (‘p’ value = 0.268) was not significant. 
         There were no statistically significant differences in mean TC levels of both 
control & study groups. 
 
Figure No: 3 shows 
 Line diagrammatic representation of  mean TC level in Table No: 3 
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Table No 4: LOW DENSITY LIPOPROTEIN 
 
 
GROUP N 
Mean 
(mg/dl) Std. Deviation ‘p’ Value 
% reduction from 
baseline 
LDL Baseline 1 30 180.73 18.605 0.061 0 
2 30 173.53 16.706  0 
LDL 2nd week 1 30 142.47 17.591 0.645 21.17 
2 30 144.67 19.139  18.66 
LDL 4th week 1 30 112.27 11.907 0.553 37.87 
2 30 110.50 11.026  35.89 
LDL 6th week 1 30 95.00 6.314 0.601 47.43 
2 30 95.77 4.890  45.61 
LDL 12thweek 1 30 90.33 6.070 0.921 48.01 
2 30 90.50 6.897  47.23 
Repeated Measures of ANOVA 
Within Group : F= 903.89 , P < 0.001 
Between Groups: F= 0.36 , P= 0.551 
P ≤ 0.05significant; P≤ 0.01  highly significant;  P≤0.001 very high significant. 
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Figure No 4:  LOW DENSITY LIPOPROTEIN 
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Table No: 4 shows 
               The mean, SD and % reduction of LDL in both the groups. 
              Statistical Analysis was done by using Student independent‘t’ test. 
              At the baseline, the mean LDL in group 1 was 180.73 mg/dl & group 2 
was 178.53mg/dl (‘p’ value =0.061; not significant).By the end of 2nd week, the 
mean LDL in group 1 was 142.47 mg/dl and in group 2 was 144.67mg/dl (‘p’ 
value = 0.645; not significant). By the end of 4
th
 week, the mean LDL in group 1 
was 112.27 mg/dl and in group 2 was 110.50 mg/dl (‘p’value= 0.553; not 
significant). 
                At the end of 6
th
 week, the mean LDL in group 1 was 95.00 mg/dl & in 
group 2 was 95.77mg/dl (‘p’value= 0.601; not significant).At the end of 12th week, 
the mean LDL in group 1 was 90.33mg/dl & in group 2 was 90.50 mg/dl 
(‘p’value= 0.921; not significant). 
                The % reduction of LDL from baseline to the end of 2
nd
 week was 
21.17% in group 1 and 18.66% in group 2, by the end of 4
th
 week was 37.87 % & 
35.89%, by the end of 6
th
 week it was 47.43% & 45.61% and by the end of 12th 
week was 48.01 % & 47.23%. 
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               Repeated measures of ANOVA – Within groups (‘p’ value <0.001) was 
significant; between groups (‘p’ value = 0.551) was not significant. 
              There were no statistically significant differences in LDL levels of both 
Control & Study groups. 
 
Figure No: 4 shows 
              Line diagrammatic representation of mean LDL level in Table No: 4 
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Table No 5 : TRIGLYCERIDE 
 
GROUP N 
Mean 
(mg/dl) 
Std. 
Deviation ‘p’ value 
% reduction 
from Baseline 
TG Baseline 1 30 254.07 19.314 0.449 0 
2 30 258.17 22.242  0 
TG 2nd week 1 30 182.23 12.945 0.290 28.27 
2 30 187.13 21.531  27.51 
TG 4thweek 1 30 131.37 11.845 0.128 48.29 
2 30 136.80 12.152  47.02 
TG 6thweek 1 30 100.10 6.733 0.439 58.67 
2 30 101.47 6.837  57.32 
TG 12thweek 1 30 94.23 6.235 0.290 59.88 
2 30 95.77 4.797 . 58.67 
Repeated Measures of ANOVA 
Within Group: F= 2277.98 , P <0.001 
Between Groups : F= 4.38, P= 0.052 
P ≤ 0.05significant;  P≤ 0.01  highly significant;  P≤0.001 very high significant. 
 
 
76 
 
Figure No 5 : TRIGLYCERIDE 
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Table No: 5 shows 
             The mean, SD and % reduction of Triglyceride in both the groups.  
             Statistical Analysis was done by using Student independent‘t’ test. 
             The mean TG level in Group 1 was 254.07 mg/dl & in Group 2 was 258.17 
mg/dl in the baseline (‘p’ value =0.449; not significant).At the end of 2nd week, 
mean TG in Group 1& Group2 was 182.23mg/dl &187.13mg/dl (‘p’ value = 0.290; 
not significant). 
              At the end of 4
th
 week, the mean TG in Groups 1& 2 was 131.37mg/dl 
&136.80 mg/dl (‘p’value= 0.128; not significant).At the end of 6th week, the mean 
TG in Group 1 was 100.10 & in Group 2 was 101.47 (‘p’value= 0.439; not 
significant).At the follow up, the mean value of TG in Group 1 was 94.23 mg/dl & 
in Group 2 was 95.77 mg/dl (‘p’value= 0.290; not significant). 
               The % reduction from baseline of TG by the end of 2
nd
 week was 28.27% 
in group 1& 27.51% in group 2, by the end of 4
th
 week was 48.29 %& 47.02%, by 
the end of 6
th
 week was 58.67% & 57.32 % and at the follow up was 59.88% & 
58.67%. 
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            Repeated measures of ANOVA – Within groups (‘p’ value <0.001) was 
significant; between groups (‘p’ value = 0.052) was not significant. 
            There were no statistically significant differences in TGL levels of both 
Control & Study groups. 
 
Figure No: 5 shows 
            Line diagrammatic representation of mean TG levels in Table No: 5 
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Table No 6: VERY LOW DENSITY LIPOPROTEIN 
P≤ 0.05 significant;  P≤ 0.01highly significant; P≤0.001very high significant. 
 
 
 
 
GROUP N Mean(mg/dl) Std. Deviation ‘p’ value 
% reduction 
from baseline 
VLDL Baseline 1 30 52.40 4.507 0.091 0 
2 30 53.23 3.730  0 
VLDL 2nd week 1 30 45.07 4.291 0.816 14.26 
2 30 47.98 4.559  13.67 
VLDL 4thweek 1 30 38.93 4.472 0.054 25.70 
2 30 40.12 4.324  24.17 
VLDL 6thweek 1 30 33.13 4.214 0.058 43.91 
2 30 32.89 4.366                     42.23 
VLDL 12thweek 1 30 30.11 2.998 0.173 46.31 
2 30 29.97 2.399  45.39 
Repeated Measures of ANOVA 
Within Group: F= 1205.70 , P<0.001 
Between Groups: F= 0.81 , P =0.373 
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Figure No 6: VERY LOW DENSITY LIPOPROTEIN 
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Table No: 6 shows 
             The mean, SD and % reduction of VLDL in both the groups.  
            Statistical Analysis was done by using Student independent‘t’ test. 
            The mean VLDL in Group 1 was 52.40mg/dl & in Group 2 was 53.23mg/dl 
in the baseline (‘p’ value =0.091; not significant). At the end of 2nd week, the mean 
VLDL in Group 1 & 2was 45.07mg/dl and 47.98mg/dl (‘p’ value = 0.816; not 
significant). 
            At the end of 4
th
 week, the mean VLDL in Group 1 was 38.93mg/dl and in 
Group 2 was 40.12mg/dl (‘p’value= 0.054; not significant).At the end of 6th week, 
the mean VLDL in Group 1 was 33.13 mg/dl and Group 2 was 32.89 mg/dl 
(‘p’value= 0.058; not significant).At the follow up, mean VLDL in Groups 1 & 2 
were 30.11 mg/dl & 29.97mg/dl (‘p’value= 0.173;not significant). 
           The % reduction of VLDL from baseline to the end of 2
nd
 week was 14.26% 
in group 1 and 13.67% in group 2, by the end of 4
th
 week was 25.70 %& 24.17%, 
by the end of 6
th
 week was 43.91% &42.23 %and at the follow up it was 46.31% & 
45.39%. 
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           Repeated measures of ANOVA – Within groups (‘p’ value <0.001) was 
significant; between groups (‘p’ value = 0.373) was not significant. 
          There were no statistically significant differences in VLDL levels of both 
Control & Study groups. 
 
Figure No: 6 shows 
          Line diagrammatic representation of mean VLDL level in Table No:6 
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 Table No 7 : HIGH DENSITY LIPOPROTEIN 
 
GROUP N Mean (mg/dl) Std. Deviation ‘p’ value 
% increase 
from baseline 
HDL Baseline 1 30 33.60 3.058 0.256 0 
2 30 34.53 3.235  0 
HDL 2nd week 1 30 38.01 3.129 0.672 16.66 
2 30 37.67 2.940  12.09 
HDL 4th week 1 30 41.97 3.499 0.120 23.91 
2 30 40.63 3.023  18.66 
HDL 6th week 1 30 43.53 3.461 0.103 31.50 
2 30 42.17 2.902 . 27.96 
HDL 12thweek 1 30 43.79 3.605 0.061 32.11 
2 30 42.97 3.824  29.32 
Repeated Measures of ANOVA 
Within Group : F= 427.18, P<0.001 
Between Groups: F=1.34 , P=0.251 
P ≤ 0.05significant;  P≤ 0.01 highly significant;  P≤0.001 very high significant. 
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Figure No 7 : HIGH DENSITY LIPOPROTEIN 
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Table No: 7 shows 
             The mean, SD and % increase of HDL in both the groups. 
             Statistical Analysis was done by using Student independent‘t’ test. 
             The mean HDL in Group 1 & 2 were 33.60 mg/dl and 34.53mg/dl in the 
baseline (‘p’ value =0.256; not significant).At the end of 2nd week, the mean HDL 
was 38.01mg/dl in Group 1 and 37.67 mg/dl in Group 2 (‘p’ value = 0.672; not 
significant). 
              By the end of 4
th
 week, mean HDL in Group 1 was 41.97mg/dl & in 
Group 2 was 40.63mg/dl (‘p’value= 0.120; not significant). By the end of 6th week, 
the mean HDL in Group 1 & 2 were 43.53mg/dl & 42.17mg/dl (‘p’value= 0.103; 
not significant).At the follow up, the mean HDL in Group 1 was 43.79 mg/dl & in 
Group 2 was 42.97 mg/dl (‘p’value= 0.061;not significant). 
              The % increase in HDL from baseline to the end of 2
nd
 week was 16.66% 
in group 1 & 12.09% in group 2, by the end of 4
th
 week it was 23.91 % & 18.66%, 
by the end of 6
th
 week the reduction was 31.50% & 27.96 % and at the follow up 
the reduction was 32.11% & 29.32%. 
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             Repeated measures of ANOVA – Within groups (‘p’ value <0.001) was 
significant; between groups (‘p’ value = 0.251) was not significant. 
             There were no statistically significant differences in HDL levels of both 
Control & Study groups. 
 
Figure No: 7 shows 
            Line diagrammatic representation of mean HDL level in Table No: 7 
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Table No: 8 TC/HDL Ratio 
S.No Weeks of 
treatment 
TC/HDL Ratio 
Control Group Study Group 
1. Baseline 8.5 8.34 
2. 2
nd
 week 5.96 6.29 
3. 4
th
 week 4.36 4.66 
4. 6
th
 week 3.66 3.73 
5. 12
th
 week 3.50 3.54 
 
Table No: 8 shows 
 The Total cholesterol : HDL ratio of control and study groups at baseline, at 
the end of 2
nd
,4
th
 ,6
th
 ,12
th
 weeks(follow up). 
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Table No 9: HEMATOLOGICAL PARAMETERS IN CONTROL GROUP 
(Paired t test) 
  Mean Std. Deviation ‘p’ Value 
Hb% Before  12.40 1.329  
After  12.60 1.192 0.089 
RBS (mg/dl) Before  145.20 21.228  
After  142.97 18.072 0.052 
B.Urea (mg/dl) Before  27.97 3.634  
After  27.67 3.078 0.231 
S.Creatinine 
(mg/dl) 
Before  .753 .0937  
After  .777 .1040 0.090 
AST (U/L) Before 29.67 4.011  
After  29.43 3.308 0.428 
ALT (U/L) Before 35.37 5.702  
After  35.57 5.212 0.467 
CPK (U/L) Before  73.77 9.457  
After 73.37 9.419 0.396 
  P ≤ 0.05  significant;  P≤ 0.01  highly significant; P≤0.001 very high significant. 
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 Table No: 9 shows 
 Hematological parameters in control group before and after the study. 
 Statistical analysis was done by using Student paired‘t’ test. 
 There were no statistically significant changes in hematological parameters 
between baseline and end of the study. 
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Table No 10: HEMATOLOGICAL PARAMETERS IN STUDY GROUP 
(Paired‘t’ test) 
  Mean Std. Deviation ‘p’ value 
Hb% Before  12.40 1.329  
After  12.60 1.192 0.831 
RBS (mg/dl) Before  146.67 22.472  
After  145.30 18.943 0.236 
B.Urea (mg/dl)  Before  27.97 3.634  
After  27.67 3.078 0.231 
S.Creatinine 
(mg/dl) 
Before  0.753 .0937  
After  0.777 .1040 0.092 
AST (U/L) Before  29.60 3.936  
After  29.43 3.308 0.562 
ALT (U/L) Before  35.40 5.512  
After  35.53 5.108 0.587 
CPK (U/L) Before  73.77 9.457  
After 73.37 9.419 0.396 
P ≤ 0.05  significant;  P≤ 0.01  highly significant; P≤0.001 very high significant. 
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Table No: 10 shows 
 Hematological parameters in study group before and after the study. 
 Statistical analysis was done by using Student paired‘t’ test. 
 There were no statistically significant differences in hematological 
parameters between baseline and end of the study. 
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Table No: 11 ADVERSE EFFECTS 
S.No Adverse Effects Group 1 (Control)  
(30) 
Group 2 (Study)  
(30) 
N % N % 
1. Epigastric distress 4 13.3% 1 3.3% 
2. Myalgia 4 13.3% 2 6.6% 
3. Fatigability 2 6.6% 0 0 
4. Joint pain 3 10% 1 3.3% 
5. Headache 2 6.6% 0 0 
                                                                                    N= Number of patients 
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Figure No: 8 Adverse Effects (No. of Patients) 
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Table No: 11 shows 
The adverse effects reported in both control & study groups. 
In control group, 4 (13.3%) patients had epigastric distress, 4 (13.3%) had 
myalgia, 2 (6.6%) complained of fatigability, 3(10%) with joint pain, 2(6.6%) 
had headache. In study group, 1(3.3%) patient had epigastric distress, 2(6.6%) 
had myalgia, 1(3.3%) had joint pain. 
Figure No: 8 shows the bar diagrammatic representation of adverse effects (No. 
of patients) of both the groups. 
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Table No: 12 Associated Diseases 
S.No Associated 
Diseases 
Group Total 
N/60 (%) Control 
(30) 
Study (30) 
N/30 % N/30 % 
1. Diabetes 8 26.7 7 23.3 15 (25%) 
2. Hypertension 12 40.0 13 43.3 25 (41.7%) 
3. DM + HT 10 33.3 10 33.3 20 (33.3%) 
 
N = Number of patients 
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Figure No : 9  Associated Diseases  
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Table No:11 shows 
 The  number and % of patients having  diabetes mellitus, hypertension, both 
diabetes mellitus & hypertension associated with dyslipidemia.  
 Group 1 (26.7%) & Group 2 (23.3%) patients  have diabetes mellitus. 
 Group 1 (40.00%) & Group 2 (43.3%)  patients have hypertension. 
 Group 1 (33.3%) & Group 2 (33.3%) patients  have DM + HT. 
 
Figure No: 9 shows 
 Bar diagrammatic representation of Table No: 11 
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DISCUSSION 
                 Cardiovascular and cerebrovascular ischemic diseases are leading 
causes of morbidity and mortality worldwide, especially in middle aged adults.A 
major cause for the development of ischemic diseases is related to dyslipidemia , 
which is the disorder of the metabolism of lipoproteins. 
                  Our study was conducted, to compare the efficacy of alternate day 
therapy of atorvastatin 10 mg & fenofibrate 160 mg with daily regime of both the 
drugs on plasma lipid profile.  
               Duration of study for each patient was 6 weeks and lipid profile was 
evaluated for both the groups at baseline, at the end of 2
nd
 week, 4
th
 week, 6
th
 week 
and then they were asked to come for the follow up at the end of 12
th
 week. 
              The results of our study showed that, the mean age of patients in control & 
study groups were 50.29 and 50.33 years. No statistically significant differences 
were seen between the groups (vide Table 1a & Figure 1a).  It was found that, most 
of the patients were in the age group of 51 to 55 years (vide Table 1b & Figure 1b). 
Hence, the study & control groups were comparable in terms of mean age & age 
distribution (%). 
                
99 
 
               The sex distribution of the patients were found to be similar in group 1 & 
group 2 and most of them were males (M: F = 56.7%: 43.3%) (Vide Table 2 & 
Figure 2). 
                From the results, it is clear that, at the end of 2
nd
 week the percent 
reduction of mean TC from baseline in control group was 20.71%. Further 
reduction seen at the end of 4
th
 week & at the end of 6
th
 week were 35.97% & 
44.16%.In study group, at the end of 2
nd
 week the % reduction of mean TC from 
baseline was 21.45% and by the end of 4
th
 & 6
th
 week the values were 34.25% and 
43.82% which were found to be almost similar to control group (Vide Table 3&Fig 
3). On comparing the control and study groups, the % reduction of mean TC from 
baseline was statistically not significant. 
                 The % reduction of mean LDL from baseline in control group was 
21.71% by the end of 2
nd
 week. It was 37.87% and 47.43% at the end of 4
th
 &6
th
 
week. In study group, at the end of 2
nd
 week the % reduction of mean LDL from 
baseline was 18.66%. By the end of 4
th
 and 6
th
 week, the values were 35.89% and 
45.61% which were almost similar to control group (Vide Table 4& Fig 4). On 
comparing both the groups there were no statistically significant differences in % 
reduction in mean LDL levels. 
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               In control group, the percent reductions of mean TG from baseline at the 
end of 2
nd
 & 4
th
 week were 28.27% and 48.29%. The percent reduction was greater 
at the end of 6
th
 week and it was 58.67%. In study group, the values at the end of 
2
nd
 & 4
th
 week were 27.51% & 47.02%. By the end of 6
th
 week, the % reduction of 
mean TG value was 57.32% almost similar to control group (Vide Table 5& Fig 
5). On comparing both groups, the % reductions of mean TG were similar & 
statistically not significant.        
                On comparing both control & study groups, the % reduction of mean 
VLDL levels at the end of 2
nd
 week were 14.26% Vs 13.67%. By the 4
th
 and 6
th
 
week, the values were 25.70% and 43.91% in control group and 24.17% and 
42.23% in study group which were almost similar and statistically not significant 
(Vide Table 6 & Fig 6). 
               The mean HDL value at the baseline in control and study group was 
33.60 mg/dl Vs 34.53 mg/dl. By the end of 2
nd
 week, the mean value was 
38.01mg/dl Vs 37.67 mg/dl.At the end of 4
th
 & 6
th
 week, there was further increase 
in mean HDL value as 41.97 mg/dl and 43.53 mg/dl in control group Vs 40.63 
mg/dl and 42.17 mg/dl in study group (Vide Table 7& Fig 7). On comparing both 
the groups, there were no statistically significant differences in mean HDL levels.    
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             By the follow up, all the lipid profile parameters were maintained as that of 
6
th
 week values. The TC: HDL ratio has been recognized as a more important 
determinant of CAD risk. While in ratio of ≤ 3.5 is considered desirable, a ratio of 
> 4.5 is associated with high risk
54
. At the baseline, both the groups showed TC: 
HDL ratio of 8.5 & 8.34. By the end of 6
th
 week, the ratio has reached the desirable 
level (Vide Table 8).  
                The % reduction values of TC, LDL, TG and VLDL for alternate day 
regime were similar to that of daily regime because of the long t ½ (~ 20 hours) of 
atorvastatin, which leads to prolonged pharmacological action. It also increases 
surface LDL receptors (upregulation) which takes up the cholesterol. Even when 
the Atorvastatin is not given daily, the upregulated LDL cholesterol remains active 
and reduces the LDL cholesterol
37
. 
               Atorvastatin is also having effect on VLDL & TGs. It can reduce TG 
level even when the plasma level is > 250 mg/dl. In study group, though 
atorvastatin and fenofibrate were given on alternate day, there was significant 
reduction in TG levels (Vide Table 5& Fig 5). This can be attributed to the indirect 
action of atorvastatin on TGs, which is by reduction of cholesterol synthesis. 
Atorvastatin also impairs VLDL particles assembly & secretion, thereby reduces 
VLDL & TG levels
37
. Similarly, increased LDL receptor expression also brings 
102 
 
down TG level by increased binding of VLDL & LDL remnant particles. This may 
be the cause of persistent effect on VLDL & TG reduction in study group. 
Atorvastatin 10 mg can reduce LDL by 30-35% with a concurrent fall of plasma 
TG level by 10-30% and a modest rise in HDL by 5-15%
55
. 
                    Fenofibrate has mean plasma t ½ of 22.1 hours. It is completely 
metabolised to fenofibric acid, an active metabolite by plasma & tissue esterases. 
This active metabolite may be responsible for the effective reduction in TGs, even 
when the drug is given on alternate days. Though fenofibrate mainly act on plasma 
TG levels, it is also having effect on LDL levels
56
. The fall in LDL level is due to 
change in the cholesterol & TG contents of LDL and also due to increased LDL 
receptors. This may contribute to persistent effect on LDL & cholesterol levels 
even though both the drugs were not given every day in study group. Fenofibrate 
has greater HDL raising effect than other fibrates
57
 .The rise in HDL is atleast in  
part due to transfer of surface lipid components from catabolized VLDL to HDL, 
and partly due to increased synthesis of HDL apoproteins (apo A-I, apo A-II)by the 
liver. In these patients, fenofibrate reduces the TG level by20- 50% and HDL is 
increased by10- 15%
57
.VLDL level is reduced upto 20% and it clears LDL level by 
20%. 
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               It is well known that atorvastatin & fenofibrate has their own adverse 
effects. In our study, in control group 4 patients had epigastric distress, 4 had 
myalgia, 2 complained of fatigability, 3 had joint pain and 2 had headache. But in 
study group, 1 patient had epigastric distress, 2 had myalgia and1 had joint pain. 
Moreover, the hepatic enzymes like AST, ALT were within normal limits and also 
CPK was normal in both the groups. There were no serious adverse events reported 
in both the groups. 
                The effect of drugs on plasma lipoproteins in daily and alternate day 
regime found to be same, though in study group the patients received atorvastatin 
10 mg on one day & fenofibrate 160 mg on other day. So in study group, the total 
dosages of the drugs given are less than that given in control group. The number of 
tablets taken by the patients in alternate day therapy was less than that of daily 
therapy. During the treatment period of 6 weeks, each patient in control group 
received 42 tablets of atorvastatin 10 mg & 42 tablets fenofibrate 160 mg. But in 
study group, each received 21 tablets of atorvastatin 10 mg & 21 tablets of 
fenofibrate160 mg. This in turn increases the patients’ compliance to the therapy in 
study group. 
                   The other added advantage is cost effectiveness of alternate regime 
than daily regime. The cost of atorvastatin 10 mg (Tab.Atorva 10) 10 tablets is 
104 
 
Rs.104.49 .The cost of fenofibrate 160 mg (Tab. Fenobate 160) 10 tablets is 
Rs.86.00.In daily regime, patients received Tab.Atorva 10mg 1 OD  for 6 weeks 
,cost about Rs.440.58 & Tab. Fenobate 160mg 1 OD for 6 weeks, cost about 
Rs.361.20. So, total cost is Rs.801.78. In alternate regime, patients received 
Tab.Atorva 10mg 1 OD on alternate days for 6 weeks, cost about Rs.220.29 & 
Tab. Fenobate 160mg 1 OD on alternate days for 6 weeks, cost about Rs.180.60. 
So, total cost is Rs.400.89. 
                 Hence, the patients in alternate regime have to spend only half the drug 
cost of that of daily regime patients. Therefore, this alternate regime is cost 
effective with the same therapeutic benefits. 
                In control group, there were 8 patients with DM, 12 with HT & 10 with 
DM and HT. In study group, there were 7 patients with DM, 13 with HT and 10 
with DM and HT.On comparing both groups, they were found to be similar. They 
are likely to be on multiple drug therapy for HT & DM. So, the alternate regime is 
better in dyslipidemic patients with associated diseases because of less cost & less 
total dose of atorvastatin and fenofibrate, with better patient compliance & lesser 
drug interactions than the daily regime. 
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Conclusion 
 
                     Alternate regime of atorvastatin 10 mg and fenofibrate 160 mg is 
equally efficacious to daily regime of both atorvastatin 10 mg and fenofibrate 160 
mg with better cost effectiveness and better patient compliance in patients with 
secondary dyslipidemia. 
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PROFORMA 
Name 
Age 
Sex 
Hospital Number 
Complaints 
Present History 
Past History 
Personal History 
Treatment History 
General Examinations: 
 Pulse 
 BP 
 Anemia 
 Pedal Edema 
 Jaundice 
Systemic Examination: 
 CVS 
 RS 
 Abdomen 
 CNS 
 
                                                       
BASELINE CHARACTERISTICS 
 
1.      Name of patient 
2.     Age 
3.     Sex 
4.    IP/OP no 
5.   Address  
 
 
6.  Drug given:   Tab. Atorvastatin 10 mg   (Hospital Supply) 
           
 
7. Drug given:    Tab. Fenobate 160 mg 
    Batch no: 
    Date of purchase: 
 
 
 
 
 
                         
BIOCHEMICAL PARAMETERS 
                  
S.no Lipid Profile Initial 2nd week 4th week 6th week % 
reduction 
1. Total Cholesterol 
(mg/dl) 
     
2. LDL (mg/dl)      
3. Triglyceride(mg/dl)      
4. VLDL(mg/dl)      
5. HDL(mg/dl)      
 
 
Other biochemical parameters measured before & after study: 
 
S.No Parameters Before study After study 
1. AST(SGOT) (U/L)   
2. ALT(SGPT) (U/L)   
3. CPK (U/L)   
4. Hb%   
5. RBS (mg/dl)   
6. Blood urea (mg/dl)   
7. S.creatinine (mg/dl)   
 
 
